Effect of Guselkumab (TREMFYA®), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

被引：0

作者：

Mease, Philip ^{[1
,2
]}

Helliwell, Philip S. ^{[3
]}

Gladman, Dafna ^{[4
]}

Poddubnyy, Denis ^{[5
]}

Baraliakos, Xenofon ^{[6
]}

Chakravarty, Soumya ^{[7
,8
]}

Kollmeier, Alexa ^{[9
]}

Xu, Xie ^{[10
]}

Sheng, Shihong ^{[10
]}

Xu, Stephen ^{[10
]}

Shawi, May ^{[11
]}

van der Heijde, Desiree ^{[12
]}

Deodhar, Atul ^{[13
]}

机构：

[1] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[4] Toronto Western Hosp, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada

[5] Charite, Dept Rheumatol, Berlin, Germany

[6] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany

[7] Janssen Sci Affairs LLC, Horsham, PA USA

[8] Drexel Univ, Coll Med, Horsham, PA USA

[9] Janssen Res & Dev LLC, La Jolla, CA USA

[10] Janssen Res & Dev LLC, Spring House, PA USA

[11] Janssen Immunol Global Commercial Strategy Org, Toronto, ON, Canada

[12] Leiden Univ, Dept Rheumatol, Med Ctr, Meerssen, Netherlands

[13] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1330

引用

页码：2760 / 2763

页数：4

共 50 条

[21] EFFICACY AND SAFETY-OF GUSELKUMAB, A NIONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Soriano, Enrique R.
Mcinnes, Iain B.
Rahman, Proton
Gottlieb, Alice R.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Xu, Xie L.
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya A.
Van der Heijde, Desiree
Mease, Philip J.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S93 - S93
[22] Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Mease, Philip
Deodhar, Atul
van der Heijde, Desiree
Behrens, Frank
Kivitz, Alan
Lehman, Tom
Wei, Lan
Nys, Marleen
Banerjee, Subhashis
Nowak, Miroslawa
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3798 - 3800
[23] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSA WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, Atul
Helliwell, Philip
Boehncke, Wolf-Henning
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Subramanian, Ramanand A.
Xu, Xie L.
Sheng, Shihong
Zhou, Bei
Gorecki, Patricia C.
Ritchlin, Christopher
RHEUMATOLOGY, 2020, 59
[24] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
Mease, Philip
van der Heijde, Desiree
Ritchlin, Christopher
Cuchacovich, Rachel
Shuler, Catherine
Lin, Chen-Yen
Vangerow, Harald
Samanta, Suvajit
Lee, Chin
Gladman, Dafna
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[25] EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
Behrens, F.
Mease, P. J.
Helliwell, P.
Shawi, M.
Noel, W.
Chakravarty, D.
Kollmeier, A.
Xu, X. L.
Xu, S.
Wang, Y.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1289 - 1290
[26] Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
Behrens, Frank
Mease, Philip
Helliwell, Philip S.
Shawi, May
Noel, Wim
Chakravarty, Soumya
Xu, Alexa Kollmeier Xie
Xu, Xie
Xu, Stephen
Wang, Yanli
Baraliakos, Xenofon
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3778 - 3780
[27] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Wallace, Daniel J.
Furie, Richard
Tanaka, Yoshiya
Kalunian, Kenneth C.
Mosca, Marta
Petri, Michelle
Dorner, Thomas
Cardiel, Mario H.
Bruce, Ian N.
Gomez, Elisa
DeLozier, Amy M.
Janes, Jonathan
Linnik, Matthew D.
de Bono, Stephanie
Silk, Maria E.
Hoffman, Robert W.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[28] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Gladman, D. D.
Mease, P. J.
Bird, P.
Soriano, E.
Chakravarty, S. D.
Shawi, M.
Xu, S.
Quinn, S.
Gong, C.
Leibowitz, E.
Tam, L. S.
Helliwell, P.
Kavanaugh, A.
Deodhar, A.
Ostergaard, M.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
[29] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Zou, Hejian
Wan, Weiguo
Xue, Yu
Sun, Lingyun
Zhang, Ning
Chen, Haiying
Shi, Xiaofei
Liu, Shengyun
Chen, Lin
Ma, Xinmei
Wei, Hua
Jiang, Zhenyu
Li, Xiaomei
Fan, Hongtao
Li, Hongbin
Li, Jingyang
Wu, Rui
Shi, Guixiu
Zhu, Jing
Kong, Xiaodan
Lu, Yuewu
Cui, Xiaojing
Zheng, Qianning
Bai, Xiaoyan
Dong, Guangchao
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242
[30] Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study
Anders, Hans-Joachim
Chan, Tak Mao
Sanchez-Guerrero, Jorge
Wofsy, David
Bensley, Karen
Kim, Lilianne
Lo, Kim Hung
Shu, Cathye
Shao, Jie
Karyekar, Chetan S.
Diamond, Betty
RHEUMATOLOGY, 2024,

← 1 2 3 4 5 →